EssilorLuxottica Research and Development Expenses 2011-2024 | ESLOY

EssilorLuxottica research and development expenses for the twelve months ending December 31, 2024 were $0M, a 0% increase year-over-year.

  • EssilorLuxottica annual research and development expenses for 2024 were $0.682B, a 6.22% increase from 2023.
  • EssilorLuxottica annual research and development expenses for 2023 were $0.642B, a 1.53% increase from 2022.
  • EssilorLuxottica annual research and development expenses for 2022 were $0.632B, a 7.72% decline from 2021.

EssilorLuxottica Research and Development Expenses 2011-2024 | ESLOY

  • EssilorLuxottica annual research and development expenses for 2024 were $0.682B, a 6.22% increase from 2023.
  • EssilorLuxottica annual research and development expenses for 2023 were $0.642B, a 1.53% increase from 2022.
  • EssilorLuxottica annual research and development expenses for 2022 were $0.632B, a 7.72% decline from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$209.7B
Boston Scientific (BSX)$154.8B
Stryker (SYK)$148.4B
Medtronic (MDT)$114.8B
Lonza Group Ag (LZAGY)$49.7B
Haleon (HLN)$43.1B
ResMed (RMD)$37.6B
GE HealthCare Technologies (GEHC)$34.9B
Agilent Technologies (A)$33.1B
Terumo (TRUMY)$24.3B
Koninklijke Philips (PHG)$23.7B
Insulet (PODD)$19.9B
Zimmer Biomet Holdings (ZBH)$18.8B
Baxter (BAX)$14.3B
Smith & Nephew SNATS (SNN)$13.1B
Sunny Optical Technology (SNPTF)$10.4B
Demant (WILYY)$8.6B
Bio-Rad Laboratories (BIO)$6.8B
Lantheus Holdings (LNTH)$5.1B
Perrigo (PRGO)$3.7B
Prestige Consumer Healthcare (PBH)$3.7B
Haemonetics (HAE)$3.5B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Envista Holdings (NVST)$3.3B
ICU Medical (ICUI)$3.1B
LeMaitre Vascular (LMAT)$1.9B
QuidelOrtho (QDEL)$1.8B
AtriCure (ATRC)$1.5B
Acuren (TIC)$1.4B
AdaptHealth (AHCO)$1.2B